MAPT and Alzheimer disease: B sides, in the NIA-AA framework, it is stated that new biomarker groups could be added when it is available, without ruling out A (Aβ) and T (pathologic tau) as the unique neuropathologic biomarker to diagnose AD and exclude other causes of dementia.